Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Eicosapentaenoic Acid: Designing Better Assays
2026-08-18
Eicosapentaenoic Acid (EPA) is more than an omega-3 lipid: it is a concentration-sensitive research tool for membrane, oxidation, and vascular assays. This guide connects EPA assay design with new evidence on lipid-driven humoral immunity while clearly separating established findings from testable hypotheses.
-
CCK-8s, NOX4, and ANP Secretion in Rat Atria
2026-08-18
The reference study identifies a signaling pathway by which sulfated cholecystokinin octapeptide stimulates atrial natriuretic peptide secretion in isolated beating rat atria. Its central finding is that CCK-8s uses a NOX4–PGC-1α–PPARα/PPARγ cascade to connect arachidonic acid signaling, controlled hydrogen peroxide production, atrial mechanics, and cardiac endocrine function.
-
Morin: Mitochondrial and Fluorescence Assay Workflows
2026-08-17
Morin combines redox, inflammatory, mitochondrial, and metal-chelation use cases in one research reagent. This guide translates its AMPD-focused biology and fluorescent aluminum-ion behavior into practical assay workflows, controls, and troubleshooting strategies without overstating clinical evidence.
-
SIRT4, Glutamine Metabolism, and Liver Fibrosis
2026-08-17
The reference study identifies SIRT4-controlled glutamine metabolism as a metabolic checkpoint in activated hepatic stellate cells. By combining GDH inhibition with SIRT4 manipulation in cellular and animal models, it shows that limiting glutamate-to-α-ketoglutarate conversion can reduce stellate-cell proliferation and fibrotic progression.
-
Tetrahydromagnolol in Translational CB2 Research
2026-08-16
Tetrahydromagnolol offers a selective pharmacology framework for connecting peripheral CB2 signaling with anti-inflammatory and analgesic biology. This thought-leadership article translates the TBXA2R–ERM metastasis findings into a disciplined strategy for testing cannabinoid signaling, cytoskeletal remodeling, and disease-relevant phenotypes without overstating an unproven mechanistic link.
-
Radioiodinated Balsalazide for UC Imaging in Mice
2026-08-15
Sanad and colleagues developed and evaluated radioiodinated balsalazide as a colon-targeted tracer for ulcerative colitis in mice. Their optimized labeling workflow produced a stable radiotracer and high uptake in ulcerated colon, supporting further investigation of balsalazide-based molecular imaging while leaving important questions about receptor specificity and clinical translation unresolved.
-
Baicalein: From 12-LOX Biology to Translation
2026-08-14
Baicalein offers a pathway-anchored framework for connecting arachidonic acid metabolism, cancer cell proliferation inhibition, apoptosis, and inflammation research. This thought-leadership perspective positions 5,6,7-trihydroxy-2-phenylchromen-4-one as a translational probe—not a presumed neuroprotective therapy—and shows how to test its value without compromising anticancer activity.
-
Caffeic Acid Phenethyl Ester in Fyn–NF-κB Models
2026-08-14
Caffeic Acid Phenethyl Ester (CAPE) can serve as a mechanistic perturbation tool for separating NF-κB-dependent inflammation from Stat3 signaling in Fyn-driven neurodegeneration models. This article connects zebrafish assay design with CAPE’s validated anti-angiogenic and tumor-invasion research applications while defining the limits of cross-model interpretation.
-
A20, Oxidized Self-DNA, and Acute Kidney Injury
2026-08-13
The reference study identifies oxidized self-DNA as an inflammatory driver in acute kidney injury and establishes A20 as an endogenous brake on this response. Its genetic, pharmacological, and peptide-based experiments connect cGAS–STING signaling to NEK7-dependent NLRP3 pyroptosis, suggesting a mechanistically focused strategy for limiting renal injury.
-
Tetrahydromagnolol: Peripheral CB2 Receptor Agonist
2026-08-13
Tetrahydromagnolol enables concentration-controlled CB2 activation while also providing a way to interrogate GPR55 antagonism in receptor and cell-based assays. This guide connects cannabinoid signaling workflows with ERM-centered motility studies, emphasizing practical controls, assay selection, and troubleshooting rather than unsupported claims of therapeutic efficacy.
-
I-BET-762 Workflow for BET Inhibition
2026-08-12
I-BET-762 is a high-affinity BET inhibitor for connecting epigenetic control with inflammatory signaling and ferroptosis experiments. This practical guide translates published BRD4–ROS–FSP1 findings into cell-based workflows, assay controls, and troubleshooting decisions for cancer biology research and preclinical inflammation studies.
-
AMPK–JAK2/STAT3 in Obesity-Related Asthma
2026-08-12
The reference study identifies reduced AMPK activity and M1 macrophage polarization as linked features of obesity-related airway inflammation. Using mouse and LPS-stimulated macrophage models, it further implicates JAK2/STAT3 signaling as a mechanistic connection that can be modulated by AMPK activation.
-
Lumiracoxib in COX-2 Muscle Injury Models
2026-08-11
Lumiracoxib enables phase-aware dissection of COX-2 signaling in inflammation, ischemia, and revascularization models. Its high COX-2 selectivity supports cleaner prostaglandin synthesis inhibition studies while revealing why inhibitor timing can change vascular outcomes.
-
A20, Oxidized Self-DNA, and AKI Inflammation
2026-08-11
A 2025 study identifies oxidized self-DNA as a driver of acute kidney injury through coordinated cGAS-STING activation and NLRP3 inflammasome-mediated pyroptosis. It further shows that A20 and an A20-derived peptide suppress this response by disrupting the NEK7-NLRP3 interaction, providing a mechanistic framework for inflammasome-focused AKI research.
-
Obeticholic Acid: Reframing Liver Fibrosis Translation
2026-08-10
Obeticholic Acid links FXR-driven bile acid control with practical translational strategies for liver fibrosis, cholestasis, hepatic inflammation, and portal hypertension research. This article integrates product-specific evidence with a 2025 immune-stromal fibrosis study to help researchers design more interpretable experiments.